WHAT IS CLAIMED IS:

1. A compound of Formula (I):



(I)

wherein:

R^1 is H, halo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, or C_{1-4} haloalkoxy;

each R^2 is independently halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, or C_{1-4} haloalkoxy;

X is a prodrug moiety;

R^3 is C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-6} cycloalkyl, or heterocycloalkyl, wherein said C_{3-6} cycloalkyl and said heterocycloalkyl are optionally substituted with 1 to 4 R^{3a} substituents, each of which is independently selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, $–L^3–O–C_{1-4}$ alkyl, $–L^3–OH$, and oxo;

each L^3 is independently selected from a bond and C_{1-4} alkylene;

each heterocycloalkyl has from 4 to 6 ring members and from 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein X is $–CH(R^c)$-O–$P(O)(OR^a)(OR^b)$, $–CH(R^c)–O–C(O)–C_{1-6}$ alkylene–CO_2H, $–CH(R^c)–O–C(O)–C_{1-6}$ alkylene–$O–P(O)(OR^a)(OR^b)$, $–CH(R^c)–O–C(O)–C_{1-6}$ alkylene–$P(O)(OR^a)(OR^b)$, $–CH(R^c)–O–C(O)–C_{1-6}$ alkylene–NR^aR^b, or $–CH(R^c)–O–C(O)–C_{1-6}$ alkylene–heterocycloalkyl, and wherein R^a and R^b are each independently H or C_{1-4} alkyl, and R^c is independently selected from hydrogen and methyl.

3. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein X is $–CH_2O–P(O)(OR^a)(OR^b)$ or $–CH_2–O–C(O)–C_{1\text{-}6}$ alkylene$–CO_2H$, for example

wherein X is $–CH_2O–P(O)(OR^a)(OR^b)$, or for example

wherein X is $–CH_2–O–C(O)–C_{1\text{-}6}$ alkylene$–CO_2H$.

4. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein X is



;

for example wherein X is



.

5. The compound of any one of claims **1** to **4**, or a pharmaceutically acceptable salt thereof, wherein R^1 is $C_{1\text{-}4}$ alkyl, for example wherein R^1 is methyl.

6. The compound of any one of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein each R^2 is independently halo, $C_{1\text{-}4}$ alkoxy, or $C_{1\text{-}4}$ haloalkoxy, for example wherein each R^2 is independently halo or $C_{1\text{-}4}$ alkoxy, or for example wherein each R^2 is independently F, Cl, or methoxy.

7. The compound of any one of claims **1** to **6**, or a pharmaceutically acceptable salt thereof, wherein n is 1, 2, or 3.

8. The compound of any one of claims **1** to **7**, or a pharmaceutically acceptable salt thereof, wherein R^3 is C_{1-4} alkyl or C_{1-4} haloalkyl, for example wherein R^3 is C_{1-4} alkyl, or for example wherein R^3 is methyl.

9. The compound of any one of claims **1** to **8**, or a pharmaceutically acceptable salt thereof, wherein R^3 is C_{3-6} cycloalkyl or heterocycloalkyl.

10. The compound of claim **1**, selected from the group consisting of:


,

, and

,

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a compound of any one of claims **1** to **10**, and at least one pharmaceutically acceptable excipient.

12. A compound of any one of claims **1** to **10**, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim **11**, for use as a medicament.

13. A compound of any one of claims **1** to **10**, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim **11**, for use in the treatment of cancer or a disease characterized by overexpression of Polθ.

14. A compound for use as claimed in claim **13**, or a composition for use as claimed in claim **13**, wherein the cancer is selected from a homologous recombinant (HR) deficient cancer, cancer characterized BRCA1 and/or BRCA2 deficiency, mutation, or reduced function, lymphoma, rhabdoid tumor, multiple myeloma, uterine cancer, gastric cancer, peripheral nervous system cancer, rhabdomyosarcoma, bone cancer, colorectal cancer, mesothelioma, breast cancer, ovarian cancer, lung cancer, fibroblast cancer, central nervous system cancer, urinary tract cancer, upper aerodigestive cancer, leukemia, kidney cancer, skin cancer, esophageal cancer, or pancreatic cancer.

15. A combination comprising a compound of any one of claims **1** to **10**, or a pharmaceutically acceptable salt thereof, and a PARP inhibitor, or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, wherein the combination is to be administered simultaneously or sequentially; for example, wherein the PARP inhibitor is Niraparib, Rucaparib, Olaparib, Talazoparib, and Veliparib, AZD5305, or AZD9574, or a pharmaceutically acceptable salt thereof.